PUBLISHER: Polaris Market Research | PRODUCT CODE: 1526400
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1526400
The Europe veterinary clinical trials market size is expected to reach USD 1,650.57 million by 2032, according to a new study by Polaris Market Research. The report "Global Drug Discovery Informatics Market Size, Share, Trends, Industry Analysis Report: By Application (Drug Discovery, Drug Development), By Mode, By Services, By End-User, and By Region (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The European veterinary clinical trials market is experiencing significant demand, driven by rising pet ownership across Europe and increasing awareness about animal health and welfare. This is fueling the need for advanced veterinary treatments and interventions. The heightened demand is prompting extensive research and development activities, leading to a surge in clinical trials for new veterinary products, including pharmaceuticals, vaccines, and medical devices.
Favorable regulatory frameworks, such as the European Union's Veterinary Medicines Regulation, further bolster this market by ensuring high standards and streamlined approval processes for veterinary medicinal products.
Technological advancements, such as digital health tools and biotechnology, are revolutionizing trial design and monitoring, leading to more efficient and effective veterinary care. As the Europe veterinary clinical trials market continues to evolve, stakeholders can capitalize on these opportunities to contribute to the advancement of veterinary medicine and improve the health and well-being of animals across Europe.
Companies developing cancer tests for animals invest in extensive research and clinical trials to ensure their products are accurate, reliable, and safe for use in veterinary clinics. The launch of cancer tests tailored for veterinary clinics underscores the increasing research efforts and clinical trials in veterinary medicine.
For instance, in April 2023, VolitionRx Limited, a multinational epigenetics company, declared the availability of its Nu. Q Vet Cancer Test via Antech, a major veterinary diagnostics company across Europe. The in-clinic test provides veterinarians with a rapid, accurate, and cost-effective cancer screening tool tailored for high-risk breeds and older dogs, delivering results in about six minutes at the point of care. This development highlights ongoing innovation and research in veterinary medicine, which is crucial for driving advancements in the European veterinary clinical trials market.
In 2023, the medicines segment accounted for the largest market share due to innovations and advancements in veterinary pharmaceuticals, which require rigorous clinical trials for validation and approval.
The academics and research centers segment is expected to witness a significant CAGR during the forecast period in the European veterinary clinical trials market because it constantly explores new treatments, vaccines, and diagnostic tools, contributing to the advancement of veterinary medicine.
The UK veterinary clinical trials market held the largest market share in 2023 due to a strong network of veterinary research institutions and universities, such as the Royal Veterinary College (RVC), which conducts extensive research and clinical trials.
The global key market players include Argenta, Veyx-Pharma GmbH, Central VetPharma Consultancy, KLIFOVET GmbH, Boehringer Ingelheim International GmbH, Ondax Scientific, Vivesto AB, Labcorp Drug Development, Merck & Co., Inc., and knoell.
Polaris Market Research has segmented the Europe veterinary clinical trials market report based on animal type, intervention, indication, end user, and country: